Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Not Available].

Anne Laurain, Stanislas Pol

    Bulletin De L'Academie Nationale De Medecine
    |June 12, 2018
    PubMed
    Summary
    This summary is machine-generated.

    Significant advancements in viral hepatitis knowledge have occurred over two decades, improving diagnosis and treatment for hepatitis B (HBV) and C (HCV). New antivirals offer high cure rates for HCV and viral suppression for HBV.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Diagnostic approach for metabolic dysfunction associated steatotic liver disease].

    La Revue du praticien·2026
    Same author

    Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis.

    Infectious diseases and therapy·2026
    Same author

    HCV Cure: To Bridge the Gaps in the Care Continuum.

    Journal of viral hepatitis·2026
    Same author

    In vivo efficacy of combined human broadly neutralizing antibodies against hepatitis B virus.

    Cell reports·2025
    Same author

    Cystic fibrosis liver disease progression in the era of elexacaftor-tezacaftor-ivacaftor.

    JHEP reports : innovation in hepatology·2025
    Same author

    Mortality risk in migrant and non-migrant individuals with chronic hepatitis B virus infection: a French hospital-based cohort study (ANRS CO22 HEPATHER).

    BMC global and public health·2025
    Same journal

    [Advances and perspectives in vascularized composite allotransplantation preservation].

    Bulletin de l'Academie nationale de medecine·2025
    Same journal

    [COVID-19: Neurological manifestations and complications during the acute phase of the disease].

    Bulletin de l'Academie nationale de medecine·2024
    Same journal

    [Role of psychological factors in post-COVID-19 condition].

    Bulletin de l'Academie nationale de medecine·2023
    Same journal

    [From the origin of Sars-CoV-2 to dangerous virology/biology].

    Bulletin de l'Academie nationale de medecine·2023
    Same journal

    [Neurological forms of long COVID in adults: Critical approach].

    Bulletin de l'Academie nationale de medecine·2023
    Same journal

    [Post-COVID-19 syndrome].

    Bulletin de l'Academie nationale de medecine·2023
    See all related articles

    Area of Science:

    • Hepatology
    • Virology
    • Infectious Diseases

    Background:

    • Viral hepatitis knowledge has expanded significantly over 20 years.
    • The spectrum of hepatotropic viruses now includes A, B, C, D, E, and G, with characterized genomes impacting pathology and treatment.
    • Epidemiology, virology, and treatment of viral hepatitis are continuously evolving.

    Purpose of the Study:

    • To review progress in understanding and managing viral hepatitis.
    • To highlight advancements in diagnostic and therapeutic approaches for acute and chronic hepatitis.
    • To discuss the impact of new treatments on patient outcomes and disease progression.

    Main Methods:

    • Review of recent scientific literature on viral hepatitis.
    • Analysis of epidemiological data and seroprevalence for HBV and HCV.

    Related Experiment Videos

  • Evaluation of current and emerging treatment strategies for HBV and HCV.

    • Main Results:

    • Second-generation nucleos(t)idic analogues provide lifelong HBV suppression in adherent patients.
    • Interferon therapy for HBV achieves sustained virosuppression in one-third of patients.
    • Direct-acting antivirals achieve over 95% cure rates for HCV, with reversible manifestations.

    Conclusions:

    • Improved understanding of viral kinetics and risk factors aids treatment decisions.
    • Advances in liver transplantation and post-transplant recurrence management enhance prognosis.
    • Effective treatments are available for HBV and HCV, with high cure rates for HCV and manageable suppression for HBV.